5JD0 Stock Chart & Stats
€1.37
-€0.04(-2.01%)
At close: 4:00 PM EST
€1.37
-€0.04(-2.01%)
Day’s Range― - ―
52-Week Range€0.03 - €0.79
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.05M
Enterprise Value€4.08
Total Cash (Recent Filing)€21.84M
Total Debt (Recent Filing)€1.25M
Price to Earnings (P/E)―
Beta3.60
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.33
Shares Outstanding23,398,983
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.27
Price to Sales (P/S)12.37
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.89
Revenue Forecast (FY)€925.71K
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA very low debt-to-equity ratio (~0.06) reduces near-term solvency risk and preserves financing optionality. Over a 2–6 month horizon this structural conservatism gives management flexibility to pursue partnerships or raise capital without immediate distress, supporting continuity of operations.
Proprietary ExpreS2 PlatformThe ExpreS2 insect-cell expression platform targets hard-to-express proteins, creating a technical moat and a specialized service offering. This durable capability addresses persistent demand in biologics R&D and diagnostics, supporting recurring contract and licensing opportunities across biotech and vaccine developers.
Multiple Monetization PathwaysHaving contract services, licensing and collaboration income provides diversified, complementary revenue levers. Structurally, this mix lets the company earn fee-for-service cash while pursuing higher-margin licensing and milestone economics, reducing dependence on any single short-term revenue source.
Bears Say
Large Persistent Cash BurnSustained negative operating cash flow (~-46m TTM) meaningfully erodes cash reserves and creates recurring financing needs. Over the medium term this raises dilution and execution risk, forces management to prioritize fundraising over growth investments, and limits runway for scaling commercial activities.
Small And Declining Revenue BaseA small, shrinking revenue base (~€3.4m TTM, -8%) constrains ability to absorb fixed costs and invest in commercialization. Structurally weak top-line traction reduces predictability of licensing or partnership milestones, making multi-quarter margin improvement and self-sustaining operations more uncertain.
Negative Gross Profit And Large Operating LossesDeeply negative gross profit and persistent operating losses indicate unfavorable unit economics or heavy R&D/production costs. Until gross margins are corrected—via pricing, efficiency or product mix—profitability cannot be achieved solely by cutting overhead, posing a structural barrier to sustainable margins.
5JD0 FAQ
What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?
ExpreS2ion Biotech Holding AB lowest stock price was €0.03 and its highest was €0.79 in the past 12 months.
What is ExpreS2ion Biotech Holding AB’s market cap?
ExpreS2ion Biotech Holding AB’s market cap is €3.05M.
When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?
ExpreS2ion Biotech Holding AB’s upcoming earnings report date is Aug 20, 2026 which is in 14 days.
How were ExpreS2ion Biotech Holding AB’s earnings last quarter?
ExpreS2ion Biotech Holding AB released its earnings results on May 28, 2026. The company reported -€0.088 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.088.
Is ExpreS2ion Biotech Holding AB overvalued?
According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued.
Does ExpreS2ion Biotech Holding AB pay dividends?
ExpreS2ion Biotech Holding AB does not currently pay dividends.
What is ExpreS2ion Biotech Holding AB’s EPS estimate?
ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ExpreS2ion Biotech Holding AB have?
ExpreS2ion Biotech Holding AB has 23,398,983 shares outstanding.
What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?
ExpreS2ion Biotech Holding AB reported an EPS of -€0.088 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.873%.
Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?
Currently, no hedge funds are holding shares in DE:5JD0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ExpreS2ion Biotech Holding AB
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipeline includes a capsid virus-like particle COVID-19 vaccine, an influenza vaccine, and a breast cancer vaccine, all of which are currently undergoing Phase II clinical trials. ExpreS2ion is also engaged in developing a malaria vaccine. Furthermore, the company extends its reach by licensing its proprietary ExpreS2 platform to various research organizations and pharmaceutical businesses. ExpreS2ion Biotech Holding AB commenced operations in 2015.